Nephritis Clinical Trial
Official title:
Uses of Baricetinib 4 mg or 2mg Versus MMF to Maintain Lupus Remission Randomized Controlled Trial: Outcomes Over 2 Years
Baricitinib a selective Janus kinase (JAK) inhibitors 1&2 have been recognized as a potential therapeutic option in systemic lupus (SLE), also known Baricitinib, a JAK inhibitor, has demonstrated efficacy and safety in the treatment of dermatitis and arthritis 1 ; however, no JAK inhibitor studies have been conducted in lupus nephritis (LN) maintain remission to date.
Baricitinib a selective Janus kinase (JAK) inhibitors 1&2 have been recognized as a potential therapeutic option in systemic lupus (SLE), also known Baricitinib, a JAK inhibitor, has demonstrated efficacy and safety in the treatment of dermatitis and arthritis 1 ; however, no JAK inhibitor studies have been conducted in lupus nephritis (LN) maintain remission to date. Objectives: To assess the efficacy and safety of Baricitinib in patients (pts) with LN by dose 4mg versus 2 mg versus MMF 1 gm daily dose. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04869462 -
DS Titanium Ligation Clip in Urology (Prostatectomy and Nephrectomy)
|
||
| Withdrawn |
NCT00508898 -
The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria
|
Phase 4 | |
| Recruiting |
NCT01172002 -
Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
|
N/A | |
| Completed |
NCT00818948 -
Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis
|
Phase 1 | |
| Terminated |
NCT04387448 -
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
|
Phase 2 | |
| Terminated |
NCT04950114 -
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
|
Phase 2 | |
| Completed |
NCT00301613 -
Mycophenolate Mofetil (MMF) Versus Intravenous CTX Pulses in the Treatment of Adult Severe HSPN
|
N/A | |
| Withdrawn |
NCT03884400 -
Distribution of Biospecimens From Biorepositories/Biobanks for Research Use
|